Circ Cardiovasc Qual Outcomes:手机调查问卷可代替临床随访评估急性卒中患者预后

2015-11-02 phylis 译 MedSci原创

背景:在许多国家,由于资源和时间有限,大多数卒中患者未能进行长期功能预后的评估。研究者调查基于手机的调查问卷的自主的mRS的评估是否可代替卒中后临床随访的mRS的评估。方法:研究者在2014年3月至5月期间招募了62名急性卒中患者入住卒中单元治疗。48名患者完成了这项研究。在住院期间,患者和/或其照顾者在他们自己手机上装一个移动应用程序。手机应用程序基于先前研究的Rankin评估,共有20个问题。

背景:在许多国家,由于资源和时间有限,大多数卒中患者未能进行长期功能预后的评估。研究者调查了基于手机的调查问卷的自主的mRS的评估是否可代替卒中后临床随访的mRS的评估。

方法:研究者在2014年3月至5月期间招募了62名急性卒中患者入住卒中单元治疗。48名患者完成了这项研究。在住院期间,患者和/或其照顾者在他们自己手机上装一个移动应用程序。手机应用程序基于先前研究的Rankin评估,共有20个问题。三个月后,手机应用程序自动提示该研究的参与者在手机上进行问卷调查。问卷中的每一个问题或每一组问题对应一个特定的mRS得分。使用预定的协议,受试者回答“是”的最高mRS得分的问题被认为是最终的mRS得分。几天后,研究者进行了一次临床随访,对患者进行mRS评估。应用二次加权κ统计比较这两次评估是否一致。

结果:平均年龄为67岁(38%为女性),国立卫生研究院卒中量表(NIHSS)基线评分为5分(四分位距为2-10.5,范围0-23)。临床随访3个月mRS的中位数和平均数分别2和2.3。研究者发现临床随访和移动mRS评估一致性为62.5%, 加权Kappa值为 0.89(95%CI为0.82-0.96),未加权Kappa值为 0.53(95%CI 0.36-0.70)。区分功能独立(mRS评分0-2分)和功能依赖(mRS评分3-5)的一致性为83%,未加权Kappa 值0.66(95%CI 0.45-0.87)。

结论:基于移动电话的自主评估的卒中患者的功能预后评分——mRS值与临床随访的mRS值一致,这说明手机可以代替临床随访进行卒中随访。

原文出处:

Cooray C, Matusevicius M, Wahlgren N, Ahmed N. Mobile Phone-Based Questionnaire for Assessing 3 Months Modified Rankin Score After Acute Stroke: A Pilot Study. Circ Cardiovasc Qual Outcomes. 2015 Oct.


版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720073, encodeId=77ef1e2007342, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Dec 05 12:21:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938522, encodeId=f57c193852219, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Feb 17 13:21:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691856, encodeId=a051169185626, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Feb 13 01:21:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284437, encodeId=c9ea128443e27, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486867, encodeId=1c8e148686e6a, content=<a href='/topic/show?id=cac69203415' target=_blank style='color:#2F92EE;'>#调查问卷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92034, encryptionId=cac69203415, topicName=调查问卷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a81b8226286, createdName=10518096zz, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590774, encodeId=96b31590e74de, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720073, encodeId=77ef1e2007342, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Dec 05 12:21:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938522, encodeId=f57c193852219, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Feb 17 13:21:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691856, encodeId=a051169185626, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Feb 13 01:21:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284437, encodeId=c9ea128443e27, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486867, encodeId=1c8e148686e6a, content=<a href='/topic/show?id=cac69203415' target=_blank style='color:#2F92EE;'>#调查问卷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92034, encryptionId=cac69203415, topicName=调查问卷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a81b8226286, createdName=10518096zz, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590774, encodeId=96b31590e74de, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=)]
    2016-02-17 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720073, encodeId=77ef1e2007342, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Dec 05 12:21:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938522, encodeId=f57c193852219, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Feb 17 13:21:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691856, encodeId=a051169185626, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Feb 13 01:21:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284437, encodeId=c9ea128443e27, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486867, encodeId=1c8e148686e6a, content=<a href='/topic/show?id=cac69203415' target=_blank style='color:#2F92EE;'>#调查问卷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92034, encryptionId=cac69203415, topicName=调查问卷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a81b8226286, createdName=10518096zz, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590774, encodeId=96b31590e74de, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720073, encodeId=77ef1e2007342, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Dec 05 12:21:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938522, encodeId=f57c193852219, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Feb 17 13:21:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691856, encodeId=a051169185626, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Feb 13 01:21:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284437, encodeId=c9ea128443e27, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486867, encodeId=1c8e148686e6a, content=<a href='/topic/show?id=cac69203415' target=_blank style='color:#2F92EE;'>#调查问卷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92034, encryptionId=cac69203415, topicName=调查问卷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a81b8226286, createdName=10518096zz, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590774, encodeId=96b31590e74de, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1720073, encodeId=77ef1e2007342, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Dec 05 12:21:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938522, encodeId=f57c193852219, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Feb 17 13:21:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691856, encodeId=a051169185626, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Feb 13 01:21:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284437, encodeId=c9ea128443e27, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486867, encodeId=1c8e148686e6a, content=<a href='/topic/show?id=cac69203415' target=_blank style='color:#2F92EE;'>#调查问卷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92034, encryptionId=cac69203415, topicName=调查问卷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a81b8226286, createdName=10518096zz, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590774, encodeId=96b31590e74de, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1720073, encodeId=77ef1e2007342, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Dec 05 12:21:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938522, encodeId=f57c193852219, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Feb 17 13:21:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691856, encodeId=a051169185626, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Feb 13 01:21:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284437, encodeId=c9ea128443e27, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486867, encodeId=1c8e148686e6a, content=<a href='/topic/show?id=cac69203415' target=_blank style='color:#2F92EE;'>#调查问卷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92034, encryptionId=cac69203415, topicName=调查问卷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a81b8226286, createdName=10518096zz, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590774, encodeId=96b31590e74de, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Wed Nov 04 12:21:00 CST 2015, time=2015-11-04, status=1, ipAttribution=)]
    2015-11-04 longqijun254

相关威廉亚洲官网

如何用spss软件处理调查问卷

    当williamhill asia 的调查问卷在把调查数据拿回来后,williamhill asia 该做的工作就是用相关的统计软件进行处理,在此,williamhill asia 以spss为处理软件,来简要说明一下问卷的处理过程,它的过程大致可分为四个过程:定义变量﹑数据录入﹑统计分析和结果保存.下面将从这四个方面来对问卷的处理做详细的介绍.Spss处理:第一步:定义变量大多数情况下williamhill asia 需要从头定义变量,在打开SPSS后,williamhill asia 可以看到和excel相似的界

Mol Psychiat:新研究发现血液测试或可预测自杀倾向

Molecular Psychiatry:新研究发现血液测试或可预测自杀倾向 近日,来自印第安纳大学医学院的一项新的研究表明,血液测试结合问卷调查或可预测一个人的自杀倾向,且其准确度可达90%,该研究成果发表于《分子精神病学》。研究人员表示,他们已经开发出一种可在病人血液中找到11个生物标志物的简单的测试,将此测试与以应用程序为基础的调查问卷结合时,便可在已接受精神治疗的患者中

部位不当脊柱手术漏报问题的调查

     部位不当的脊柱手术算是漏报问题吗?   研究者呼吁要更多强调使用最好手术操作以防止手术失误。   “部位不当的脊柱手术是警讯事件,常常报告给联合委员会,”罗切斯特梅奥医院骨科教授Bradford Currier博士在2012颈椎研究学会年会上报告指出。   “据报告,明尼苏达州大约30%部位不当手术是错误节段的脊柱手术,”他继续说。“尽管存在发生

调查问卷的信度和效度检验的SPSS理论与实战

(一)信度1 、信度的含义测验的信度又称测验的可靠性 , 是指同一个测验对同一组被试施测两次或多次 , 所得结果一致形程度。一个好的测验必须是稳定可靠的 , 多次使用所获得的结果是前后一致的。例如 , 用直尺测量长度 , 其结果是稳定可靠的 ; 用橡皮筋测长度则是不

调查问卷中多选题的spss数据录入与分析

    在调查问卷设计过程中,通常会设计各种多选题,甚至排序题,来进行信息的搜集,而这些多选题或排序题又是必不可少的,因此就需要对各种多选题、排序题进行录入和分析,在这里以spss的录入和分析为例,来讨论下多选题和排序题的录入及分析。 1多选题的录入和分析 多选题一般有三种情况,一种是任选几项,不限定选择项数;一种是限定最多选择几项,比如最多选择三项等;